[go: up one dir, main page]

JO3332B1 - مشتقات 5- فلورو-n- (بيريدين-2-يل) بيريدين -2-أمين تحتوي على مجموعة سلفوكسيمين - Google Patents

مشتقات 5- فلورو-n- (بيريدين-2-يل) بيريدين -2-أمين تحتوي على مجموعة سلفوكسيمين

Info

Publication number
JO3332B1
JO3332B1 JOP/2013/0330A JOP20130330A JO3332B1 JO 3332 B1 JO3332 B1 JO 3332B1 JO P20130330 A JOP20130330 A JO P20130330A JO 3332 B1 JO3332 B1 JO 3332B1
Authority
JO
Jordan
Prior art keywords
pyridin
fluoro
amine derivatives
derivatives containing
sulfoximine group
Prior art date
Application number
JOP/2013/0330A
Other languages
English (en)
Inventor
Arne Scholz Dr
Ulrich Lücking Dr
Ulf Bӧmer Dr
Gerhard Siemeister Dr
Dirk Kosemund Dr
Rolf Bohlmann Dr
Philip Lienau Dr
Niels Bӧhnke Dr
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Application granted granted Critical
Publication of JO3332B1 publication Critical patent/JO3332B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

يتعلق الاختراع الحالي بمشتقات 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine محتوية على مجموعة sulfoximine من الصيغة العامة (I) كما هو موصوف ومحدد هنا، وطرق لتحضيرها، استخدامها لمعالجة و/أو الوقاية من اضطرابات، بالتحديد اضطرابات فرط انقسام الخلية و/أو أمراض معدية يحثها فيروس و/أو أمراض قلبية وعائية. يتعلق الاختراع أيضا بمركبات وسطية مفيدة في تحضير المركبات المذكورة من الصيغة العامة (I).
JOP/2013/0330A 2012-11-15 2013-11-13 مشتقات 5- فلورو-n- (بيريدين-2-يل) بيريدين -2-أمين تحتوي على مجموعة سلفوكسيمين JO3332B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12192852 2012-11-15

Publications (1)

Publication Number Publication Date
JO3332B1 true JO3332B1 (ar) 2019-03-13

Family

ID=47148672

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2013/0330A JO3332B1 (ar) 2012-11-15 2013-11-13 مشتقات 5- فلورو-n- (بيريدين-2-يل) بيريدين -2-أمين تحتوي على مجموعة سلفوكسيمين

Country Status (42)

Country Link
US (2) US9650340B2 (ar)
EP (1) EP2928878B1 (ar)
JP (1) JP6263193B2 (ar)
KR (1) KR102242871B1 (ar)
CN (1) CN105102444B (ar)
AP (1) AP3872A (ar)
AR (1) AR093505A1 (ar)
AU (1) AU2013346939B2 (ar)
BR (1) BR112015010707B1 (ar)
CA (1) CA2891358C (ar)
CL (1) CL2015001304A1 (ar)
CR (1) CR20150256A (ar)
CU (1) CU20150052A7 (ar)
CY (1) CY1118441T1 (ar)
DK (1) DK2928878T3 (ar)
DO (1) DOP2015000118A (ar)
EA (1) EA027226B1 (ar)
EC (1) ECSP15019323A (ar)
ES (1) ES2612978T3 (ar)
HR (1) HRP20161547T1 (ar)
HU (1) HUE032868T2 (ar)
IL (1) IL238322A (ar)
JO (1) JO3332B1 (ar)
LT (1) LT2928878T (ar)
MA (1) MA38090B1 (ar)
ME (1) ME02880B (ar)
MX (1) MX374333B (ar)
MY (1) MY170609A (ar)
NZ (1) NZ707084A (ar)
PE (1) PE20151071A1 (ar)
PH (1) PH12015501003B1 (ar)
PL (1) PL2928878T3 (ar)
PT (1) PT2928878T (ar)
RS (1) RS55580B1 (ar)
SG (1) SG11201503079PA (ar)
SI (1) SI2928878T1 (ar)
SV (1) SV2015004979A (ar)
TN (1) TN2015000185A1 (ar)
TW (1) TWI613193B (ar)
UA (1) UA115254C2 (ar)
UY (1) UY35141A (ar)
WO (1) WO2014076091A1 (ar)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
TWI555737B (zh) 2011-05-24 2016-11-01 拜耳知識產權公司 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
CA2888371C (en) 2012-10-18 2021-06-08 Ulrich Lucking 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group
CN105283453B (zh) 2012-10-18 2018-06-22 拜耳药业股份公司 含砜基的n-(吡啶-2-基)嘧啶-4-胺衍生物
UA115254C2 (uk) 2012-11-15 2017-10-10 Баєр Фарма Акціенгезельшафт Похідні 5-фтор-n-(піридин-2-іл)піридин-2-аміну, що містять сульфоксімінову групу
TW201418243A (zh) 2012-11-15 2014-05-16 Bayer Pharma AG 含有磺醯亞胺基團之ｎ－（吡啶－２－基）嘧啶－４－胺衍生物
EP2931712B8 (en) 2012-12-17 2018-05-23 Parion Sciences, Inc. 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
RU2015129065A (ru) 2012-12-17 2017-01-25 Пэрион Сайенсиз, Инк. Производные хлор-пиразинкарбоксамида, обладающие активностью блокирования эпителиальных натриевых каналов
WO2015001021A1 (en) * 2013-07-04 2015-01-08 Bayer Pharma Aktiengesellschaft Sulfoximine substituted 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives and their use as cdk9 kinase inhibitors
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
CN106232596A (zh) 2014-03-13 2016-12-14 拜耳医药股份有限公司 含有砜基团的5‑氟‑n‑(吡啶‑2‑基)吡啶‑2‑胺衍生物
EP3126338B1 (en) 2014-04-01 2019-09-04 Bayer Pharma Aktiengesellschaft Disubstituted 5-fluoro pyrimidine derivatives containing a sulfondiimine group
AP2016009483A0 (en) 2014-04-11 2016-10-31 Bayer Pharma AG Novel macrocyclic compounds
CN107207475A (zh) 2014-10-16 2017-09-26 拜耳医药股份有限公司 含有砜基团的氟化苯并呋喃基‑嘧啶衍生物
ES2691227T3 (es) 2014-10-16 2018-11-26 Bayer Pharma Aktiengesellschaft Derivados fluorados de benzofuranil-pirimidina que contienen un grupo sulfoximina
WO2017055196A1 (en) 2015-09-29 2017-04-06 Bayer Pharma Aktiengesellschaft Novel macrocyclic sulfondiimine compounds
ES2819869T3 (es) 2015-10-08 2021-04-19 Bayer Pharma AG Nuevos compuestos macrocíclicos modificados
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
WO2018177899A1 (en) 2017-03-28 2018-10-04 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
US11242356B2 (en) 2017-03-28 2022-02-08 Bayer Aktiengesellschaft PTEFb inhibiting macrocyclic compounds
CA3090843A1 (en) * 2018-02-13 2019-08-22 Bayer Aktiengesellschaft Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-n-{4-[(s-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large b-cell lymphoma
JP2023505850A (ja) 2019-12-09 2023-02-13 石薬集団中奇制薬技術（石家庄）有限公司 サイクリン依存性キナーゼ９阻害剤としての化合物及びその用途
JP2023517034A (ja) * 2020-03-06 2023-04-21 バイエル アクチェンゲゼルシャフト Ｃｄｋ１２の阻害を介してがんに作用するイミダゾトリアジン
WO2022078309A1 (zh) * 2020-10-12 2022-04-21 上海海雁医药科技有限公司 取代的二(吡啶-2-基)胺衍生物、其组合物及医药上的用途
CN117015539A (zh) * 2022-03-25 2023-11-07 成都苑东生物制药股份有限公司 一种氨基吡啶类衍生物、其制备方法及用途
WO2024044757A1 (en) * 2022-08-26 2024-02-29 Sanford Burnham Prebys Medical Discovery Institute Aminopyrimidine and aminotriazine derivatives as myc protein modulators
AU2023374476A1 (en) * 2022-11-02 2025-06-19 Lead Discovery Center Gmbh Combination therapies comprising a cdk9 inhibitor for cancer
WO2024112656A1 (en) * 2022-11-21 2024-05-30 The Board Of Trustees Of The Leland Stanford Junior University Use of a tyrosine kinase inhibitor for the treatment of hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2432000C (en) 2000-12-21 2011-03-15 Glaxo Group Limited Pyrimidineamines as angiogenesis modulators
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
DE10349423A1 (de) * 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
MX2007007272A (es) 2004-12-17 2007-07-11 Astrazeneca Ab 4-(4-imidazol-4-il)pirimidin-2-ilamino)benzamidas como inhibidores de cdk.
DE102006041382A1 (de) * 2006-08-29 2008-03-20 Bayer Schering Pharma Ag Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren
DE102006042143A1 (de) 2006-09-08 2008-03-27 Bayer Healthcare Aktiengesellschaft Neue substituierte Bipyridin-Derivate und ihre Verwendung
WO2008060248A1 (en) 2006-11-15 2008-05-22 S*Bio Pte Ltd. Indole sustituted pyrimidines and use thereof in the treatment of cancer
JP2010514689A (ja) 2006-12-22 2010-05-06 ノバルティス アーゲー 癌、炎症およびウイルス感染症の処置のためのｃｄｋ阻害剤としてのヘテロアリール−ヘテロアリール化合物
CN101568530A (zh) 2006-12-22 2009-10-28 诺瓦提斯公司 吲哚-4-基-嘧啶-2-基胺衍生物及其作为细胞周期蛋白依赖性激酶抑制剂的用途
US8507498B2 (en) 2007-04-24 2013-08-13 Ingenium Pharmaceuticals Gmbh 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases
ES2539518T3 (es) 2007-04-24 2015-07-01 Astrazeneca Ab Inhibidores de proteínas quinasas
JP5379787B2 (ja) 2007-04-24 2013-12-25 インゲニウム ファーマシューティカルズ ジーエムビーエイチ プロテインキナーゼの阻害剤
WO2008132138A1 (en) 2007-04-25 2008-11-06 Ingenium Pharmaceuticals Gmbh Derivatives of 4,6-disubstituted aminopyrimidines
WO2009029998A1 (en) 2007-09-06 2009-03-12 Cytopia Research Pty Ltd Retrometabolic compounds
GB0805477D0 (en) 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
US8415381B2 (en) 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
JP5921525B2 (ja) 2010-03-22 2016-05-24 リード ディスカバリー センター ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬的に活性のある二置換のトリアジン誘導体
WO2012101063A1 (en) * 2011-01-28 2012-08-02 Novartis Ag N-acyl pyridine biaryl compounds and their uses
WO2012117059A1 (en) * 2011-03-02 2012-09-07 Lead Discovery Center Gmbh Pharmaceutically active disubstituted pyridine derivatives
EP2527332A1 (en) 2011-05-24 2012-11-28 Bayer Intellectual Property GmbH 4-Aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group as CDK9 inhibitors
ES2587284T3 (es) 2011-09-16 2016-10-21 Bayer Intellectual Property Gmbh 5-Fluoro-pirimidinas 2,4-disustituidas como inhibidores selectivos de CDK9
EP2755948B1 (en) 2011-09-16 2016-05-25 Bayer Intellectual Property GmbH Disubstituted 5-fluoro pyrimidine derivatives containing a sulfoximine group
US20150259300A1 (en) 2012-10-18 2015-09-17 Bayer Pharma Aktiengesellschaft 4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amines containing a sulfone group
CA2888371C (en) * 2012-10-18 2021-06-08 Ulrich Lucking 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group
UA115254C2 (uk) 2012-11-15 2017-10-10 Баєр Фарма Акціенгезельшафт Похідні 5-фтор-n-(піридин-2-іл)піридин-2-аміну, що містять сульфоксімінову групу
US9499492B2 (en) 2012-11-15 2016-11-22 Bayer Pharma Aktiengesellschaft 4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amines containing a sulfoximine group
WO2015001021A1 (en) 2013-07-04 2015-01-08 Bayer Pharma Aktiengesellschaft Sulfoximine substituted 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives and their use as cdk9 kinase inhibitors
CN106232596A (zh) 2014-03-13 2016-12-14 拜耳医药股份有限公司 含有砜基团的5‑氟‑n‑(吡啶‑2‑基)吡啶‑2‑胺衍生物

Also Published As

Publication number Publication date
CN105102444A (zh) 2015-11-25
CL2015001304A1 (es) 2015-07-17
RS55580B1 (sr) 2017-06-30
CU20150052A7 (es) 2015-09-29
SI2928878T1 (sl) 2016-12-30
DK2928878T3 (en) 2016-12-19
KR20150084968A (ko) 2015-07-22
UA115254C2 (uk) 2017-10-10
HUE032868T2 (en) 2017-11-28
EA027226B1 (ru) 2017-07-31
WO2014076091A1 (en) 2014-05-22
AR093505A1 (es) 2015-06-10
PL2928878T3 (pl) 2017-04-28
NZ707084A (en) 2019-09-27
BR112015010707B1 (pt) 2022-05-17
HRP20161547T1 (hr) 2016-12-30
ME02880B (me) 2018-04-20
CN105102444B (zh) 2017-08-01
MX374333B (es) 2025-03-06
BR112015010707A8 (pt) 2019-10-01
EP2928878B1 (en) 2016-11-02
SV2015004979A (es) 2017-01-30
TN2015000185A1 (en) 2016-10-03
SG11201503079PA (en) 2015-06-29
US9877954B2 (en) 2018-01-30
ES2612978T3 (es) 2017-05-19
AU2013346939B2 (en) 2017-06-08
ECSP15019323A (es) 2016-01-29
AP3872A (en) 2016-10-31
PH12015501003B1 (en) 2017-10-20
PH12015501003A1 (en) 2015-07-27
UY35141A (es) 2014-06-30
LT2928878T (lt) 2016-11-25
US20150291528A1 (en) 2015-10-15
US20170202815A1 (en) 2017-07-20
AP2015008432A0 (en) 2015-05-31
CA2891358A1 (en) 2014-05-22
IL238322A (en) 2017-08-31
AU2013346939A1 (en) 2015-05-14
EA201590890A1 (ru) 2015-11-30
MX2015006169A (es) 2015-08-10
PE20151071A1 (es) 2015-08-19
CR20150256A (es) 2015-07-01
MY170609A (en) 2019-08-20
TW201420569A (zh) 2014-06-01
EP2928878A1 (en) 2015-10-14
PT2928878T (pt) 2017-02-08
JP2015537015A (ja) 2015-12-24
BR112015010707A2 (pt) 2017-07-11
CA2891358C (en) 2021-05-18
IL238322A0 (en) 2015-06-30
US9650340B2 (en) 2017-05-16
DOP2015000118A (es) 2015-06-15
CY1118441T1 (el) 2017-06-28
MA38090A1 (fr) 2018-02-28
HK1213255A1 (zh) 2016-06-30
KR102242871B1 (ko) 2021-04-20
JP6263193B2 (ja) 2018-01-17
TWI613193B (zh) 2018-02-01
MA38090B1 (fr) 2018-09-28

Similar Documents

Publication Publication Date Title
TN2015000185A1 (en) 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group
TN2013000485A1 (en) 4-aryl-n-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group
WO2014060375A3 (en) 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group
CA2917096C (en) Sulfoximine substituted 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives and their use as cdk9 kinase inhibitors
TN2015000186A1 (en) N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfoximine group
MX2013012233A (es) 4-aril-n-fenil-1,3,5-triazin-2-aminas sustituidas.
MX2015007916A (es) Peri-carbinoles.
WO2014060493A3 (en) N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfone group
PH12015500347A1 (en) 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
JO3453B1 (ar) مشتقات البنزاميد لتثبيط نشاط abl1 و abl2 و bcr-abl1
PH12016501968A1 (en) Novel macrocyclic compounds
PH12014501967B1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
CA2878796C (en) Derivatives of pyridinone as inhibitors for tissue transglutaminase
TN2015000095A1 (en) Macrolide derivatives, preparation thereof and therapeutic use thereof
PH12015502703A1 (en) Pharmaceutical compositions
NZ622558A (en) Hiv replication inhibitors
TH148747A (th) 4-อัลริล-n-ฟีนิล-1,3,5-ไตรอะซิน-2-เอมีนที่มีหมู่ซัลโฟซิมีน